Physician profile
Robert A Mills
NPI 1174629208
$1,789.63
in general payments reported to CMS, 2019-2025
33 companies · $370 in 2025
The $370 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $190 · 2021: $71.99 · 2022: $110 · 2023: $230 · 2024: $340 · 2025: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $939.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $939.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $184.17 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $158.70 | 2019-2025 | Tepezza |
| Xeris Pharmaceuticals, INC. | $140.32 | 2021-2024 | Gvoke Hypopen |
| Abbvie INC. | $133.54 | 2019-2024 | |
| Lilly USA, LLC | $106.06 | 2020-2025 | Jardiance, Zepbound, Mounjaro |
| Antares Pharma, INC. | $93.85 | 2024 | Xyosted |
| Astrazeneca Pharmaceuticals LP | $92.00 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.29 | 2020-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $62.88 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.58 | 2019-2020 | |
| Cequr Corporation | $57.12 | 2025 | Cequr Simplicity |
| Ascensia Diabetes Care US INC. | $54.25 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $50.13 | 2019-2021 | |
| Medtronic, INC. | $43.95 | 2024-2025 | Minimed 780g |
| Janssen Pharmaceuticals, INC | $41.63 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $41.42 | 2020 | |
| Mannkind Corporation | $39.26 | 2025 | |
| Insulet Corporation | $35.85 | 2023 | Omnipod |
| Tandem Diabetes Care, INC. | $35.30 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Glaxosmithkline, LLC. | $33.11 | 2019 | |
| Dexcom, INC. | $28.98 | 2024 | Dexcom G6 Transmitter |
| Jazz Pharmaceuticals INC. | $28.06 | 2024 | |
| Avadel Cns Pharmaceuticals, LLC | $27.54 | 2025 | Lumryz |
| Abbott Laboratories | $27.03 | 2024 | Freestyle Libre 3 |
| Amneal Pharmaceuticals LLC | $24.11 | 2019 | |
| Allergan, INC. | $20.31 | 2020 | |
| Exact Sciences Corporation | $16.54 | 2025 | Cologuard Collection Kit |
| Pfizer INC. | $14.41 | 2025 | |
| Horizon Therapeutics Plc | $14.06 | 2023 | Tepezza |
| Arbor Pharmaceuticals, INC. | $13.90 | 2019 | |
| Radius Health, INC. | $13.75 | 2021 | |
| Janssen Biotech, INC. | $13.20 | 2019 | |
| Ibsa Pharma INC. | $12.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.